A Phase 0/I Pharmacokinetic and Pharmacodynamics and Safety and Tolerability Study of Letrozole in Combination with Standard Therapy in Recurrent High-Grade Gliomas

20247 citationsJournal Article

Authors

On the basis of safety, brain tumoral PK, and mechanistic data, 15 mg daily is identified as the RP2D for future trials.

Good health and well-being

Published in: Clinical Cancer Research

Volume 30, Issue 10, pp. 2068-2077

Field-Weighted Citation Impact: 3.07